This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
BeneFIX® (nonacog alfa) is recombinant coagulation factor IX indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX can be used for all age groups.1
Prophylactic treatment in PTPs
93% of responses were rated as excellent or effective (n=47).2*
Prophylactic treatment in PUPs
91% of responses were rated as excellent (n=42), indicating that spontaneous muscoloskeletal bleeding was prevented.3†
Paediatric patients
77% of patients under 6 years old with severe Haemophilia B experienced no spontaneous bleeding episodes while on prophylaxis (n=22).4
On-demand treatment PTPs
81% of 1796 bleeding episodes were resolved with only 1 infusion (n=55).2
On-demand treatment PUPs
75% of 997 bleeding episodes were resolved with only 1 infusion (n=54).3
Surgery
97% of responses were rated excellent or good (n=28).5§†
Adverse reactions cited as very common (≥10%): headaches, cough and pyrexia1
Adverse reactions cited as common (≥1% to <10%): hypersensitivity, dizziness, dysgeusia, phlebitis, flushing, vomiting, nausea, rash, urticaria, chest discomfort, infusion-site reaction and pain1
Adverse reactions cited as uncommon (≥0.1% to <1%): Infusion-site cellulitis, Factor IX inhibition, somnolence, tremor, visual impairment, tachycardia, hypotension, renal infarct1
Access information to help determine adequate dosing for your patient and improve their peak control.
Find out more on how to administer and store BeneFIX using our R2 device.
Contact us for more information on BeneFIX and download our FAQ for supply and stock related queries.
Abbreviations:
PTP, previously treated patients; PUP, previously untreated patients.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024